{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:51:50Z","timestamp":1790859110689,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI165077"],"award-info":[{"award-number":["P01AI165077"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23wm0125002"],"award-info":[{"award-number":["JP23wm0125002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP233fa627001"],"award-info":[{"award-number":["JP233fa627001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP233fa827005"],"award-info":[{"award-number":["JP233fa827005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59533-4","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:07:14Z","timestamp":1747177634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform"],"prefix":"10.1038","volume":"16","author":[{"given":"Makoto","family":"Kuroda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1648-1625","authenticated-orcid":false,"given":"Peter J.","family":"Halfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-1922","authenticated-orcid":false,"given":"Ryuta","family":"Uraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5157","authenticated-orcid":false,"given":"Seiya","family":"Yamayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taksoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy A.","family":"Armbrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Spyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Dahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Babujee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-8296","authenticated-orcid":false,"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"59533_CR1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1126\/science.add2897","volume":"377","author":"EJ Wherry","year":"2022","unstructured":"Wherry, E. J. & Barouch, D. H. T cell immunity to COVID-19 vaccines. Science 377, 821\u2013822 (2022).","journal-title":"Science"},{"key":"59533_CR2","doi-asserted-by":"publisher","first-page":"eadd4853","DOI":"10.1126\/sciimmunol.add4853","volume":"7","author":"J Tang","year":"2022","unstructured":"Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci. Immunol. 7, eadd4853 (2022).","journal-title":"Sci. Immunol."},{"key":"59533_CR3","doi-asserted-by":"publisher","first-page":"910136","DOI":"10.3389\/fimmu.2022.910136","volume":"13","author":"A Rice","year":"2022","unstructured":"Rice, A. et al. Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. Front Immunol. 13, 910136 (2022).","journal-title":"Front Immunol."},{"key":"59533_CR4","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.ymthe.2022.04.014","volume":"30","author":"S McCafferty","year":"2022","unstructured":"McCafferty, S. et al. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. Mol. Ther. 30, 2968\u20132983 (2022).","journal-title":"Mol. Ther."},{"key":"59533_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","volume":"185","author":"S Afkhami","year":"2022","unstructured":"Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 185, 896\u2013915.e819 (2022).","journal-title":"Cell"},{"key":"59533_CR6","doi-asserted-by":"publisher","first-page":"eabq1945","DOI":"10.1126\/scitranslmed.abq1945","volume":"14","author":"RL Hajnik","year":"2022","unstructured":"Hajnik, R. L. et al. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Sci. Transl. Med. 14, eabq1945 (2022).","journal-title":"Sci. Transl. Med."},{"key":"59533_CR7","doi-asserted-by":"publisher","first-page":"815389","DOI":"10.3389\/fmed.2022.815389","volume":"9","author":"S Thakur","year":"2022","unstructured":"Thakur, S. et al. SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. Front. Med. (Lausanne) 9, 815389 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"59533_CR8","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3390\/vaccines11121810","volume":"11","author":"A Rak","year":"2023","unstructured":"Rak, A., Isakova-Sivak, I. & Rudenko, L. Overview of Nucleocapsid-Targeting Vaccines against COVID-19. Vaccines (Basel) 11, 1810 (2023).","journal-title":"Vaccines (Basel)"},{"key":"59533_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38751-8","volume":"14","author":"W Tai","year":"2023","unstructured":"Tai, W. et al. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants. Nat. Commun. 14, 2962 (2023).","journal-title":"Nat. Commun."},{"key":"59533_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","volume":"185","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847\u2013859 e811 (2022).","journal-title":"Cell"},{"key":"59533_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","volume":"603","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 603, 493\u2013496 (2022).","journal-title":"Nature"},{"key":"59533_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489\u20131501.e1415 (2020).","journal-title":"Cell"},{"key":"59533_CR13","doi-asserted-by":"crossref","unstructured":"Mao T. et al. Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses. bioRxiv, (2022).","DOI":"10.1101\/2022.01.24.477597"},{"key":"59533_CR14","doi-asserted-by":"publisher","first-page":"100520","DOI":"10.1016\/j.xcrm.2022.100520","volume":"3","author":"H Ishii","year":"2022","unstructured":"Ishii, H. et al. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8(+) T cell responses. Cell Rep. Med. 3, 100520 (2022).","journal-title":"Cell Rep. Med."},{"key":"59533_CR15","doi-asserted-by":"publisher","first-page":"109664","DOI":"10.1016\/j.celrep.2021.109664","volume":"36","author":"T Dangi","year":"2021","unstructured":"Dangi, T., Class, J., Palacio, N., Richner, J. M. & Penaloza MacMaster, P. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep. 36, 109664 (2021).","journal-title":"Cell Rep."},{"key":"59533_CR16","doi-asserted-by":"publisher","first-page":"729837","DOI":"10.3389\/fimmu.2021.729837","volume":"12","author":"E Gabitzsch","year":"2021","unstructured":"Gabitzsch, E. et al. Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge. Front. Immunol. 12, 729837 (2021).","journal-title":"Front. Immunol."},{"key":"59533_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19819-1","volume":"11","author":"F Chiuppesi","year":"2020","unstructured":"Chiuppesi, F. et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat. Commun. 11, 6121 (2020).","journal-title":"Nat. Commun."},{"key":"59533_CR18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41564-023-01352-8","volume":"8","author":"G Nouailles","year":"2023","unstructured":"Nouailles, G. et al. Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nat. Microbiol. 8, 860\u2013874 (2023).","journal-title":"Nat. Microbiol."},{"key":"59533_CR19","doi-asserted-by":"publisher","first-page":"eabk0172","DOI":"10.1126\/sciadv.abk0172","volume":"7","author":"J Trimpert","year":"2021","unstructured":"Trimpert, J. et al. Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). Sci. Adv. 7, eabk0172 (2021).","journal-title":"Sci. Adv."},{"key":"59533_CR20","doi-asserted-by":"publisher","first-page":"e2102775118","DOI":"10.1073\/pnas.2102775118","volume":"118","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc. Natl. Acad. Sci. USA 118, e2102775118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59533_CR21","doi-asserted-by":"publisher","first-page":"109493","DOI":"10.1016\/j.celrep.2021.109493","volume":"36","author":"J Trimpert","year":"2021","unstructured":"Trimpert, J. et al. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Rep. 36, 109493 (2021).","journal-title":"Cell Rep."},{"key":"59533_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31930-z","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat. Commun. 13, 4337 (2022).","journal-title":"Nat. Commun."},{"key":"59533_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3390\/vaccines8040584","volume":"8","author":"SH Seo","year":"2020","unstructured":"Seo, S. H. & Jang, Y. Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection. Vaccines (Basel) 8, 584 (2020).","journal-title":"Vaccines (Basel)"},{"key":"59533_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/v15010095","volume":"15","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine. Viruses 15, 95 (2022).","journal-title":"Viruses"},{"key":"59533_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.vaccine.2022.12.019","volume":"41","author":"E Faizuloev","year":"2023","unstructured":"Faizuloev, E. et al. Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity. Vaccine 41, 892\u2013902 (2023).","journal-title":"Vaccine"},{"key":"59533_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1056\/NEJMp2307867","volume":"389","author":"X Becerra","year":"2023","unstructured":"Becerra, X. & Jha, A. Project NextGen - Defeating SARS-CoV-2 and Preparing for the Next Pandemic. N. Engl. J. Med. 389, 773\u2013775 (2023).","journal-title":"N. Engl. J. Med."},{"key":"59533_CR27","doi-asserted-by":"publisher","first-page":"104585","DOI":"10.1016\/j.ebiom.2023.104585","volume":"92","author":"D Pilapitiya","year":"2023","unstructured":"Pilapitiya, D., Wheatley, A. K. & Tan, H. X. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine 92, 104585 (2023).","journal-title":"EBioMedicine"},{"key":"59533_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23779-5","volume":"12","author":"AA Amarilla","year":"2021","unstructured":"Amarilla, A. A. et al. A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses. Nat. Commun. 12, 3431 (2021).","journal-title":"Nat. Commun."},{"key":"59533_CR29","doi-asserted-by":"publisher","first-page":"109014","DOI":"10.1016\/j.celrep.2021.109014","volume":"35","author":"S Torii","year":"2021","unstructured":"Torii, S. et al. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction. Cell Rep. 35, 109014 (2021).","journal-title":"Cell Rep."},{"key":"59533_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/pathogens12020301","volume":"12","author":"ZH Tun","year":"2023","unstructured":"Tun, Z. H., Htike, N. T. T., Kyi-Tha-Thu, C. & Lee, W. H. Employing T-Cell Memory to Effectively Target SARS-CoV-2. Pathogens 12, 301 (2023).","journal-title":"Pathogens"},{"key":"59533_CR31","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."},{"key":"59533_CR32","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","volume":"184","author":"RP Payne","year":"2021","unstructured":"Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699\u20135714 e5611 (2021).","journal-title":"Cell"},{"key":"59533_CR33","doi-asserted-by":"publisher","first-page":"eabj9853","DOI":"10.1126\/science.abj9853","volume":"374","author":"J Mateus","year":"2021","unstructured":"Mateus, J. et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science 374, eabj9853 (2021).","journal-title":"Science"},{"key":"59533_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","volume":"22","author":"A Singanayagam","year":"2022","unstructured":"Singanayagam, A. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect. Dis. 22, 183\u2013195 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"59533_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u2013286.e278 (2023).","journal-title":"Cell"},{"key":"59533_CR36","doi-asserted-by":"publisher","first-page":"e0094824","DOI":"10.1128\/jvi.00948-24","volume":"98","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1. J. Virol. 98, e0094824 (2024).","journal-title":"J. Virol."},{"key":"59533_CR37","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/j.cell.2021.02.044","volume":"184","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. Cell 184, 2229\u20132238.e2213 (2021).","journal-title":"Cell"},{"key":"59533_CR38","doi-asserted-by":"publisher","first-page":"103841","DOI":"10.1016\/j.ebiom.2022.103841","volume":"76","author":"A Alu","year":"2022","unstructured":"Alu, A. et al. Intranasal COVID-19 vaccines: From bench to bed. EBioMedicine 76, 103841 (2022).","journal-title":"EBioMedicine"},{"key":"59533_CR39","doi-asserted-by":"publisher","first-page":"943331","DOI":"10.3389\/fimmu.2022.943331","volume":"13","author":"M Zhang","year":"2022","unstructured":"Zhang, M., Li, N., He, Y., Shi, T. & Jie, Z. Pulmonary resident memory T cells in respiratory virus infection and their inspiration on therapeutic strategies. Front. Immunol. 13, 943331 (2022).","journal-title":"Front. Immunol."},{"key":"59533_CR40","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","volume":"34","author":"AT Tan","year":"2021","unstructured":"Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728 (2021).","journal-title":"Cell Rep."},{"key":"59533_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41591-020-01143-2","volume":"27","author":"I Schulien","year":"2021","unstructured":"Schulien, I. et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells. Nat. Med. 27, 78\u201385 (2021).","journal-title":"Nat. Med."},{"key":"59533_CR42","doi-asserted-by":"publisher","first-page":"11034","DOI":"10.1128\/JVI.01505-14","volume":"88","author":"R Channappanavar","year":"2014","unstructured":"Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J. Virol. 88, 11034\u201311044 (2014).","journal-title":"J. Virol."},{"key":"59533_CR43","doi-asserted-by":"publisher","first-page":"ofab143","DOI":"10.1093\/ofid\/ofab143","volume":"8","author":"AD Redd","year":"2021","unstructured":"Redd, A. D. et al. CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. Open Forum Infect. Dis. 8, ofab143 (2021).","journal-title":"Open Forum Infect. Dis."},{"key":"59533_CR44","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","volume":"2","author":"A Tarke","year":"2021","unstructured":"Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2, 100355 (2021).","journal-title":"Cell Rep. Med."},{"key":"59533_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell 183, 158\u2013168.e114 (2020).","journal-title":"Cell"},{"key":"59533_CR46","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41590-021-00902-8","volume":"22","author":"J Zuo","year":"2021","unstructured":"Zuo, J. et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 22, 620\u2013626 (2021).","journal-title":"Nat. Immunol."},{"key":"59533_CR47","doi-asserted-by":"publisher","first-page":"100354","DOI":"10.1016\/j.xcrm.2021.100354","volume":"2","author":"KW Cohen","year":"2021","unstructured":"Cohen, K. W. et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep. Med. 2, 100354 (2021).","journal-title":"Cell Rep. Med."},{"key":"59533_CR48","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.it.2024.06.003","volume":"45","author":"A Izadi","year":"2024","unstructured":"Izadi, A. & Nordenfelt, P. Protective non-neutralizing SARS-CoV-2 monoclonal antibodies. Trends Immunol. 45, 609\u2013624 (2024).","journal-title":"Trends Immunol."},{"key":"59533_CR49","doi-asserted-by":"publisher","first-page":"e29527","DOI":"10.1002\/jmv.29527","volume":"96","author":"HT Zedan","year":"2024","unstructured":"Zedan, H. T. et al. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines. J. Med. Virol. 96, e29527 (2024).","journal-title":"J. Med. Virol."},{"key":"59533_CR50","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59533_CR51","doi-asserted-by":"crossref","unstructured":"Kim D.K., et al. A Comprehensive, Flexible Collection of SARS-CoV-2 Coding Regions. G3 (Bethesda) 10, 3399\u20133402 (2020).","DOI":"10.1534\/g3.120.401554"},{"key":"59533_CR52","doi-asserted-by":"publisher","first-page":"e210653511","DOI":"10.1073\/pnas.2106535118","volume":"118","author":"M Imai","year":"2021","unstructured":"Imai, M. et al. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc. Natl Acad. Sci. USA 118, e210653511 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59533_CR53","doi-asserted-by":"publisher","first-page":"110394","DOI":"10.1016\/j.celrep.2022.110394","volume":"38","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. Cell Rep. 38, 110394 (2022).","journal-title":"Cell Rep."},{"key":"59533_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45495-6","volume":"15","author":"PJ Halfmann","year":"2024","unstructured":"Halfmann, P. J. et al. Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine. Nat. Commun. 15, 1284 (2024).","journal-title":"Nat. Commun."},{"key":"59533_CR55","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-022-05482-7","volume":"612","author":"R Uraki","year":"2022","unstructured":"Uraki, R. et al. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612, 540\u2013545 (2022).","journal-title":"Nature"},{"key":"59533_CR56","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/infdis\/jiab587","volume":"225","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters. J. Infect. Dis. 225, 282\u2013286 (2022).","journal-title":"J. Infect. Dis."},{"key":"59533_CR57","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/v16101625","volume":"16","author":"SA Gibson","year":"2024","unstructured":"Gibson, S. A. et al. Differences in Susceptibility to SARS-CoV-2 Infection Among Transgenic hACE2-Hamster Founder Lines. Viruses-Basel 16, 1625 (2024).","journal-title":"Viruses-Basel"},{"key":"59533_CR58","doi-asserted-by":"publisher","first-page":"107764","DOI":"10.1016\/j.isci.2023.107764","volume":"26","author":"T Gilliland","year":"2023","unstructured":"Gilliland, T. et al. Transchromosomic bovine-derived anti-SARS-CoV-2 polyclonal human antibodies protects hACE2 transgenic hamsters against multiple variants. Iscience 26, 107764 (2023).","journal-title":"Iscience"},{"key":"59533_CR59","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s42003-021-02128-8","volume":"4","author":"S Chiba","year":"2021","unstructured":"Chiba, S. et al. Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. Commun. Biol. 4, 597 (2021).","journal-title":"Commun. Biol."},{"key":"59533_CR60","doi-asserted-by":"publisher","first-page":"104341","DOI":"10.1016\/j.ebiom.2022.104341","volume":"86","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. EBioMedicine 86, 104341 (2022).","journal-title":"EBioMedicine"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59533-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:03:59Z","timestamp":1747181039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59533-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59533"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59533-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Shionogi & Co. LTD, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation, and Fuji Rebio. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4453"}}